Recent Research Analysts’ Ratings Changes for Abivax (ABVX)

A number of firms have modified their ratings and price targets on shares of Abivax (NASDAQ: ABVX) recently:

• 6/3/2026 – Abivax was given a new $136.00 price target by Wolfe Research.
• 6/3/2026 – Abivax had its “outperform” rating reaffirmed by Wolfe Research.
• 6/2/2026 – Abivax had its price target lowered by Truist Financial Corporation from $140.00 to $135.00. They now have a “buy” rating on the stock.
• 6/2/2026 – Abivax had its price target lowered by Morgan Stanley from $145.00 to $132.00. They now have an “overweight” rating on the stock.
• 6/2/2026 – Abivax had its “outperform” rating reaffirmed by Citigroup Inc..
• 6/2/2026 – Abivax was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $90.00 price target on the stock, down from $160.00.
• 6/2/2026 – Abivax had its price target raised by Citizens Jmp from $131.00 to $187.00. They now have a “market outperform” rating on the stock.
• 6/2/2026 – Abivax was upgraded by Wedbush from “underperform” to “neutral”. They now have a $90.00 price target on the stock, down from $110.00.
• 6/2/2026 – Abivax had its “buy” rating reaffirmed by BTIG Research. They now have a $150.00 price target on the stock.
• 5/26/2026 – Abivax had its “market outperform” rating reaffirmed by Citigroup Inc..
• 5/26/2026 – Abivax had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $131.00 price target on the stock.
• 5/23/2026 – Abivax was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/26/2026 – Abivax was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/20/2026 – Abivax had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/18/2026 – Abivax was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/9/2026 – Abivax had its “outperform” rating reaffirmed by Oddo Bhf.

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.